文献速递胸部肿瘤

肿瘤浸润淋巴细胞密度与晚期非小细胞肺癌免疫治疗良好预后相关

Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
PubMed 文献 · Eur J Cancer · 2021-01-27

这项多中心回顾性研究分析了纳武利尤单抗队列221例和化疗队列189例晚期NSCLC患者,评估间质TIL密度(高TIL定义为≥10%)与生存的关系。高TIL在免疫治疗队列中占22%,与OS(HR 0.48;95%CI 0.28-0.81)和PFS(HR 0.40;95%CI 0.25-0.64)改善相关,并与ORR和DCR相关(均P<.0001);化疗队列中高TIL占37%,与PFS和OS无关联。

要点

  • 高TIL(≥10%)与纳武利尤单抗治疗的OS和PFS改善独立相关。
  • 高TIL组中位PFS 13.0个月 vs 低TIL组2.2个月。
  • 化疗队列中TIL密度与PFS和OS均无关联。

核心结论

  • 在真实世界免疫治疗队列中,高TIL与晚期NSCLC患者 favourable 结局相关,而化疗队列无此关联,提示TIL可能有助于筛选免疫治疗获益人群。

研究设计与样本

  • 多中心回顾性研究,纳武利尤单抗队列221例(2012年11月至2017年2月治疗),化疗队列189例(2009年6月至2016年10月治疗),分析有组织标本可行间质TIL评估的患者。

主要发现

  • 免疫治疗队列中高TIL占22%,与OS(HR 0.48;95%CI 0.28-0.81)和PFS(HR 0.40;95%CI 0.25-0.64)相关。
  • 高TIL组中位PFS为13.0个月(95%CI 5.0-未达到),低TIL组为2.2个月(95%CI 1.7-3.0)。
  • 高TIL组中位OS未达到(95%CI 12.2-未达到),低TIL组为8.4个月(95%CI 5.0-11.6)。
  • 高TIL与ORR和DCR相关(均P<.0001)。
  • 化疗队列中高TIL占37%,中位PFS 5.7个月(95%CI 4.9-6.7),中位OS 11.7个月(95%CI 9.3-13.0),与TIL无关联。

关键数值与推荐

  • 高TIL定义为间质TIL密度≥10%。
  • 免疫治疗队列:高TIL与OS的HR为0.48(95%CI 0.28-0.81),与PFS的HR为0.40(95%CI 0.25-0.64)。

临床怎么用

  • 对于晚期NSCLC患者,评估间质TIL密度(≥10%为高TIL)可能有助于识别更可能从免疫检查点抑制剂治疗中获益的人群。

局限性

  • 回顾性研究设计,可能存在选择偏倚。
  • 化疗队列与免疫治疗队列的治疗时期不同,存在时间偏倚。
  • TIL评估仅基于形态学,未报告评估者间一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The established role of morphological evaluation of tumour-infiltrating lymphocytes (TILs) with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) is unknown. We aimed to determine TIL association with the outcome for ICIs and for chemotherapy in advanced NSCLC. METHODS: This is a multicenter retrospective study of a nivolumab cohort of 221 patients treated between November 2012 and February 2017 and a chemotherapy cohort of 189 patients treated between June 2009 and October 2016. Patients with available tissue for stromal TIL evaluation were analysed. The presence of a high TIL count (high-TIL) was defined as ≥10% density. The primary end-point was overall survival (OS). RESULTS: Among the nivolumab cohort, 64% were male, with median age of 63 years, 82.3% were smokers, 77% had performance status ≤1 and 63% had adenocarcinoma histology. High-TIL was observed in 22% patients and associated with OS (hazard ratio [HR] 0.48; 95% confidence interval [95% CI]: 0.28-0.81) and progression-free survival [PFS] (HR = 0.40; 95% CI: 0.25-0.64). Median PFS was 13.0 months (95% CI: 5.0-not reached) with high-TIL versus 2.2 months (95% CI: 1.7-3.0) with the presence of a low TIL count (low-TIL). Median OS for high-TIL was not reached (95% CI: 12.2-not reached) versus 8.4 months (95% CI: 5.0-11.6) in the low-TIL group. High-TIL was associated with the overall response rate (ORR) and disease control rate (DCR) (both, P < .0001). Among the chemotherapy cohort, 69% were male, 89% were smokers, 86% had performance status ≤1 and 90% had adenocarcinoma histology. High-TIL was seen in 37%. Median PFS and OS were 5.7 months (95% CI: 4.9-6.7) and 11.7 months (95% CI: 9.3-13.0), respectively, with no association with TILs. CONCLUSIONS: High-TIL was associated with favourable outcomes in a real-world immunotherapy cohort of patients with NSCLC, but not with chemotherapy, suggesting that TILs may be useful in selecting patients for immunotherapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gataa I, Mezquita L, Rossoni C, et al. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. Eur J Cancer. 2021. PMID: 33516050. doi:10.1016/j.ejca.2020.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。